JP2013515693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515693A5 JP2013515693A5 JP2012545302A JP2012545302A JP2013515693A5 JP 2013515693 A5 JP2013515693 A5 JP 2013515693A5 JP 2012545302 A JP2012545302 A JP 2012545302A JP 2012545302 A JP2012545302 A JP 2012545302A JP 2013515693 A5 JP2013515693 A5 JP 2013515693A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- composition
- lipid
- group
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 28
- 150000002632 lipids Chemical class 0.000 claims 18
- 125000002947 alkylene group Chemical group 0.000 claims 12
- -1 cationic lipid Chemical class 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 230000000975 bioactive effect Effects 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 230000009368 gene silencing by RNA Effects 0.000 claims 6
- 239000004055 small Interfering RNA Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims 5
- 230000007935 neutral effect Effects 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims 4
- 229930182558 Sterol Natural products 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000003431 steroids Chemical class 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims 3
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 210000005229 liver cell Anatomy 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 238000006116 polymerization reaction Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims 2
- 229950005143 sitosterol Drugs 0.000 claims 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims 2
- 235000016831 stigmasterol Nutrition 0.000 claims 2
- 229940032091 stigmasterol Drugs 0.000 claims 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims 1
- VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 claims 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- HVYWMOMLDIMFJA-VEIPTCAHSA-N (3r,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-VEIPTCAHSA-N 0.000 claims 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 claims 1
- XZEUYTKSAYNYPK-UHFFFAOYSA-N 3beta-29-Norcycloart-24-en-3-ol Natural products C1CC2(C)C(C(CCC=C(C)C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 XZEUYTKSAYNYPK-UHFFFAOYSA-N 0.000 claims 1
- 229930188104 Alkylresorcinol Natural products 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 239000004380 Cholic acid Substances 0.000 claims 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims 1
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 claims 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 claims 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 claims 1
- LPFIPZJIWTZLEY-UHFFFAOYSA-N Dinosterol Natural products C1CC2C(C)C(O)CCC2(C)C2C1C1CCC(C(C)C=C(C)C(C)C(C)C)C1(C)CC2 LPFIPZJIWTZLEY-UHFFFAOYSA-N 0.000 claims 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims 1
- 108010007979 Glycocholic Acid Proteins 0.000 claims 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims 1
- HVXLSFNCWWWDPA-UHFFFAOYSA-N Isocycloartenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCCC(C)=C)C)CCC3(C)C1CC2 HVXLSFNCWWWDPA-UHFFFAOYSA-N 0.000 claims 1
- 108010044467 Isoenzymes Proteins 0.000 claims 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims 1
- 102000011931 Nucleoproteins Human genes 0.000 claims 1
- 108010061100 Nucleoproteins Proteins 0.000 claims 1
- HXQRIQXPGMPSRW-UHZRDUGNSA-N Pollinastanol Natural products O[C@@H]1C[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@H]([C@H](CCCC(C)C)C)CC5)CC4)CC2)C3)CC1 HXQRIQXPGMPSRW-UHZRDUGNSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 claims 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 229940076810 beta sitosterol Drugs 0.000 claims 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims 1
- 235000004420 brassicasterol Nutrition 0.000 claims 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims 1
- 235000000431 campesterol Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims 1
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 claims 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 1
- 229960002471 cholic acid Drugs 0.000 claims 1
- 235000019416 cholic acid Nutrition 0.000 claims 1
- ONQRKEUAIJMULO-YBXTVTTCSA-N cycloartenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 ONQRKEUAIJMULO-YBXTVTTCSA-N 0.000 claims 1
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 claims 1
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 claims 1
- LPFIPZJIWTZLEY-DAABMGJCSA-N dinosterol Chemical compound C[C@@H]([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)/C=C(\C)[C@H](C)C(C)C)[C@@]2(C)CC1 LPFIPZJIWTZLEY-DAABMGJCSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 229960002061 ergocalciferol Drugs 0.000 claims 1
- ZKQRGSXITBHHPC-VVQHAZRASA-N ergosta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 ZKQRGSXITBHHPC-VVQHAZRASA-N 0.000 claims 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 claims 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 1
- 229940099347 glycocholic acid Drugs 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000223 polyglycerol Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 235000015500 sitosterol Nutrition 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 1
- 235000001892 vitamin D2 Nutrition 0.000 claims 1
- 239000011653 vitamin D2 Substances 0.000 claims 1
- 239000012991 xanthate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28478709P | 2009-12-23 | 2009-12-23 | |
| US61/284,787 | 2009-12-23 | ||
| PCT/EP2010/070412 WO2011076807A2 (en) | 2009-12-23 | 2010-12-21 | Lipids, lipid compositions, and methods of using them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015196915A Division JP6166321B2 (ja) | 2009-12-23 | 2015-10-02 | 脂質、脂質組成物およびそれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013515693A JP2013515693A (ja) | 2013-05-09 |
| JP2013515693A5 true JP2013515693A5 (OSRAM) | 2014-02-13 |
Family
ID=43857652
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012545302A Withdrawn JP2013515693A (ja) | 2009-12-23 | 2010-12-21 | 脂質、脂質組成物およびそれらの使用方法 |
| JP2015196915A Active JP6166321B2 (ja) | 2009-12-23 | 2015-10-02 | 脂質、脂質組成物およびそれらの使用方法 |
| JP2017122319A Active JP6585659B2 (ja) | 2009-12-23 | 2017-06-22 | 脂質、脂質組成物およびそれらの使用方法 |
| JP2019162148A Active JP6940567B2 (ja) | 2009-12-23 | 2019-09-05 | 脂質、脂質組成物およびそれらの使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015196915A Active JP6166321B2 (ja) | 2009-12-23 | 2015-10-02 | 脂質、脂質組成物およびそれらの使用方法 |
| JP2017122319A Active JP6585659B2 (ja) | 2009-12-23 | 2017-06-22 | 脂質、脂質組成物およびそれらの使用方法 |
| JP2019162148A Active JP6940567B2 (ja) | 2009-12-23 | 2019-09-05 | 脂質、脂質組成物およびそれらの使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110200582A1 (OSRAM) |
| EP (2) | EP3721943A1 (OSRAM) |
| JP (4) | JP2013515693A (OSRAM) |
| KR (1) | KR101762466B1 (OSRAM) |
| CN (1) | CN102905763B (OSRAM) |
| AR (1) | AR079745A1 (OSRAM) |
| AU (1) | AU2010334911A1 (OSRAM) |
| BR (1) | BR112012015755B1 (OSRAM) |
| CA (2) | CA2785492C (OSRAM) |
| EA (1) | EA026374B1 (OSRAM) |
| MX (1) | MX348474B (OSRAM) |
| SG (2) | SG181904A1 (OSRAM) |
| TW (1) | TWI549699B (OSRAM) |
| WO (1) | WO2011076807A2 (OSRAM) |
Families Citing this family (228)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3338765T3 (en) | 2009-12-01 | 2019-03-04 | Translate Bio Inc | STEROID DERIVATIVE FOR THE SUPPLY OF MRNA IN HUMANGENETIC DISEASES |
| SG181904A1 (en) * | 2009-12-23 | 2012-07-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
| WO2012006380A2 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Cationic oil-in-water emulsions |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX341989B (es) | 2010-08-31 | 2016-09-09 | Novartis Ag * | Liposomas pequeños para el suministro de arn que codifica el inmunogeno. |
| HUE061068T2 (hu) | 2010-08-31 | 2023-05-28 | Glaxosmithkline Biologicals Sa | Pegilált liposzómák immunogént kódoló RNS szállítására |
| EP3542789A3 (en) * | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| CN103429606A (zh) | 2010-10-01 | 2013-12-04 | 现代治疗公司 | 设计核酸及其使用方法 |
| EP4098324A1 (en) | 2010-10-11 | 2022-12-07 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| JP6184945B2 (ja) | 2011-06-08 | 2017-08-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法 |
| BR112014000235A8 (pt) * | 2011-07-06 | 2018-03-06 | Novartis Ag | emulsões de óleo em água catiônicas |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| SG10201605512WA (en) | 2011-07-06 | 2016-09-29 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| EP2750707B1 (en) | 2011-08-31 | 2018-10-24 | GlaxoSmithKline Biologicals SA | Pegylated liposomes for delivery of immunogen-encoding rna |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012315965A1 (en) | 2011-09-27 | 2014-04-03 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted PEGylated lipids |
| KR20190099538A (ko) | 2011-10-03 | 2019-08-27 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도 |
| PT107924A (pt) | 2011-10-21 | 2014-12-03 | Abbvie Inc | Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv |
| ES2572329B1 (es) | 2011-10-21 | 2017-08-24 | Abbvie Inc. | Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US9061063B2 (en) | 2011-12-07 | 2015-06-23 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| ES2762873T3 (es) | 2012-03-29 | 2020-05-26 | Translate Bio Inc | Lípidos catiónicos ionizables |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243954A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| MX2014013367A (es) | 2012-05-02 | 2014-12-08 | Novartis Ag | Composiciones organicas para tratar enfermedades relacionadas con kras. |
| CN109810977A (zh) | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
| DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| CA2902393C (en) | 2013-02-28 | 2022-11-01 | Arrowhead Research Corporation | Organic compositions to treat epas1-related diseases |
| WO2014136086A1 (en) | 2013-03-08 | 2014-09-12 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| JP6586075B2 (ja) | 2013-03-14 | 2019-10-02 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| IL305374A (en) | 2013-03-14 | 2023-10-01 | Ethris Gmbh | Cftr mrna compositions and related methods and uses |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| KR101514320B1 (ko) | 2013-06-14 | 2015-04-22 | 재단법인 의약바이오컨버젼스연구단 | 신규한 암 예방 또는 치료용 약학적 조성물 |
| AU2014315287A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3954360B1 (en) | 2013-09-16 | 2025-02-12 | Glycomine, Inc. | Pharmaceutical preparation of carbohydrates for therapeutic use |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| US9988627B2 (en) | 2013-10-04 | 2018-06-05 | Novartis Ag | Formats for organic compounds for use in RNA interference |
| EP3052107B1 (en) | 2013-10-04 | 2018-05-02 | Novartis AG | Organic compounds to treat hepatitis b virus |
| EP3722277A3 (en) | 2013-10-04 | 2021-01-20 | Novartis AG | 3'end caps for rna-interferring agents for use in rna |
| WO2015051135A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compositions to treat hepcidin-related diseases |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| EA034103B1 (ru) | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| AU2014340155B2 (en) | 2013-10-22 | 2018-11-01 | Massachusetts Institute Of Technology | Lipid formulations for delivery of messenger RNA |
| EP3083556B1 (en) * | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| CN106061466A (zh) | 2013-12-19 | 2016-10-26 | 诺华股份有限公司 | 瘦蛋白mRNA组合物和制剂 |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3088524A4 (en) | 2013-12-26 | 2017-08-09 | Tokyo Medical University | Artificial mimic mirna for controlling gene expression, and use of same |
| CA2935022A1 (en) | 2013-12-27 | 2015-07-02 | Bonac Corporation | Artificial match-type mirna for controlling gene expression and use therefor |
| KR102396026B1 (ko) | 2014-01-21 | 2022-05-09 | 안자리움 바이오사이언시스 아게 | 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도 |
| EP3556353A3 (en) | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| PT3981437T (pt) | 2014-04-23 | 2025-01-15 | Modernatx Inc | Vacinas de ácidos nucleicos |
| MX373952B (es) | 2014-04-25 | 2020-07-13 | Shire Human Genetic Therapies | Métodos de purificación de arn mensajero. |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| MA48050A (fr) | 2014-05-30 | 2020-02-12 | Translate Bio Inc | Lipides biodégradables pour l'administration d'acides nucléiques |
| EA033966B1 (ru) | 2014-06-24 | 2019-12-13 | Транслейт Био, Инк. | Стереохимически обогащенные композиции для доставки нуклеиновых кислот |
| HUE060907T2 (hu) * | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| AU2015283954B2 (en) * | 2014-07-02 | 2020-11-12 | Translate Bio, Inc. | Encapsulation of messenger RNA |
| US10342761B2 (en) | 2014-07-16 | 2019-07-09 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2016011123A1 (en) | 2014-07-16 | 2016-01-21 | Arrowhead Research Corporation | Organic compositions to treat apoc3-related diseases |
| US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| US10125092B2 (en) | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| AU2015368293B2 (en) | 2014-12-27 | 2021-07-22 | Bonac Corporation | Naturally occuring miRNA for controlling gene expression, and use of same |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| EP3276003B1 (en) | 2015-03-27 | 2022-07-20 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
| CN104922141B (zh) * | 2015-05-28 | 2016-05-25 | 厦门成坤生物技术有限公司 | 一种用于治疗乙型病毒性肝炎的siRNA组合物 |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| US10221127B2 (en) | 2015-06-29 | 2019-03-05 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| SMT202200178T1 (it) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Composti e composizioni per il rilascio intracellulare di agenti terapeutici |
| JP6990176B2 (ja) | 2015-10-05 | 2022-02-03 | モデルナティエックス インコーポレイテッド | メッセンジャーリボ核酸薬物の治療投与のための方法 |
| WO2017066707A1 (en) * | 2015-10-14 | 2017-04-20 | Life Technologies Corporation | Ribonucleoprotein transfection agents |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| PL3394030T3 (pl) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Związki i kompozycje do wewnątrzkomórkowego dostarczania środków |
| SI3394093T1 (sl) | 2015-12-23 | 2022-05-31 | Modernatx, Inc. | Metode uporabe liganda OX40, ki kodira polinukleotid |
| SG11201805217XA (en) | 2015-12-28 | 2018-07-30 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| MA43587A (fr) | 2016-01-10 | 2018-11-14 | Modernatx Inc | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 |
| WO2017123652A1 (en) | 2016-01-11 | 2017-07-20 | Verndari, Inc. | Microneedle compositions and methods of using same |
| CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| MA45290A (fr) * | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| US10967057B2 (en) | 2016-06-02 | 2021-04-06 | Glaxosmithkline Biologicals S.A. | Zika viral antigen constructs |
| CN109562153A (zh) | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | mRNA介导的免疫方法 |
| CN110312799A (zh) | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和系统 |
| EP4485466A3 (en) | 2016-08-17 | 2025-04-02 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| WO2018047148A1 (en) | 2016-09-12 | 2018-03-15 | Novartis Ag | Compounds for the inhibition of mirna |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| US20190314486A1 (en) | 2016-10-21 | 2019-10-17 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| BE1025121B1 (fr) | 2016-11-17 | 2018-11-05 | Glaxosmithkline Biologicals Sa | Constructions antigeniques du virus zika |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| EP3585417B1 (en) | 2017-02-27 | 2023-02-22 | Translate Bio, Inc. | Method of making a codon-optimized cftr mrna |
| LT3596041T (lt) | 2017-03-15 | 2023-01-25 | Modernatx, Inc. | Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys |
| AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
| AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| CN116693411A (zh) | 2017-04-28 | 2023-09-05 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
| EP3624824B1 (en) | 2017-05-16 | 2024-07-10 | Translate Bio, Inc. | Codon-optimized mrna encoding cftr for use in treating cystic fibrosis |
| EP3625342B1 (en) | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| ES3003260T3 (en) | 2017-06-15 | 2025-03-10 | Access To Advanced Health Inst | Nanostructured lipid carriers and stable emulsions and uses thereof |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| US12065396B2 (en) | 2017-08-17 | 2024-08-20 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| JP7379325B2 (ja) * | 2017-08-31 | 2023-11-14 | ライフ テクノロジーズ コーポレイション | 組織特異的送達用のカチオン性脂質組成物 |
| CN111315359A (zh) | 2017-08-31 | 2020-06-19 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US10597657B2 (en) | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
| CA3073848A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| KR102751412B1 (ko) | 2017-11-06 | 2025-01-09 | 닛토덴코 가부시키가이샤 | 생물학적 활성 분자의 전달을 위한 융합성 화합물 |
| US20210236644A1 (en) | 2017-11-10 | 2021-08-05 | Cocoon Biotech Inc. | Ocular applications of silk-based products |
| US12018080B2 (en) | 2017-11-13 | 2024-06-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway |
| WO2019094984A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells |
| EP3728575A4 (en) | 2017-12-22 | 2021-11-24 | The Broad Institute, Inc. | CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF DNA BASES |
| MA51230A (fr) | 2018-01-29 | 2021-05-05 | Merck Sharp & Dohme | Protéines f rsv stabilisées et leurs utilisations |
| WO2020033601A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
| EP3836963A2 (en) | 2018-08-17 | 2021-06-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions and uses thereof |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
| CA3113436A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US12329857B2 (en) | 2018-09-21 | 2025-06-17 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| IL317488A (en) | 2018-10-02 | 2025-02-01 | Intellia Therapeutics Inc | Ionizable lipid amines |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| IL314386A (en) | 2018-12-05 | 2024-09-01 | Intellia Therapeutics Inc | amine modified lipids |
| MX2021008261A (es) | 2019-01-09 | 2021-08-16 | Arrowhead Pharmaceuticals Inc | Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso. |
| AU2020205717B2 (en) | 2019-01-11 | 2025-09-11 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
| KR20250152113A (ko) | 2019-04-25 | 2025-10-22 | 인텔리아 테라퓨틱스, 인크. | 이온화 가능한 아민 지질 및 지질 나노입자 |
| JP2022542032A (ja) | 2019-07-21 | 2022-09-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 治療用ウイルスワクチン |
| BR112022004759A2 (pt) | 2019-09-19 | 2022-06-21 | Modernatx Inc | Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos |
| WO2021061707A1 (en) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein b (apob) gene expression |
| CA3147643A1 (en) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression |
| JP2023506842A (ja) | 2019-12-18 | 2023-02-20 | ノバルティス アーゲー | 異常ヘモグロビン症の治療用組成物及び方法 |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| EP4103227A1 (en) | 2020-02-14 | 2022-12-21 | Merck Sharp & Dohme LLC | Hpv vaccine |
| WO2021183720A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| EP4135761A1 (en) | 2020-04-16 | 2023-02-22 | GlaxoSmithKline Biologicals S.A. | Sars cov-2 spike protein construct |
| WO2021233352A1 (zh) * | 2020-05-19 | 2021-11-25 | 上海交通大学 | 一种细胞内吞释放响应的化合物及其应用 |
| EP4153747A2 (en) | 2020-05-22 | 2023-03-29 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
| WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| WO2022002783A1 (en) | 2020-06-29 | 2022-01-06 | Glaxosmithkline Biologicals Sa | Adjuvants |
| AU2021308681A1 (en) | 2020-07-16 | 2023-03-09 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| AU2021335334A1 (en) | 2020-09-04 | 2023-04-20 | Access To Advanced Health Institute | Genetically-adjuvanted rna vaccines |
| CA3173941A1 (en) | 2020-09-04 | 2022-03-10 | Emily VOIGT | Live-attenuated rna hybrid vaccine technology |
| CA3174411A1 (en) | 2020-09-04 | 2022-03-10 | Ryan M. Kramer | Co-lyophilized rna and nanostructured lipid carrier |
| WO2022081750A1 (en) | 2020-10-14 | 2022-04-21 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | Glaxosmithkline Biologicals Sa | Rna vaccine against sars-cov-2 variants |
| WO2022137128A2 (en) | 2020-12-23 | 2022-06-30 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
| EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20240181037A1 (en) | 2021-03-26 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| KR20240017791A (ko) | 2021-04-17 | 2024-02-08 | 인텔리아 테라퓨틱스, 인크. | Dna-의존적 단백질 키나제의 억제제 및 이의 조성물 및 용도 |
| MX2023012235A (es) | 2021-04-17 | 2024-01-23 | Intellia Therapeutics Inc | Composiciones de nanopartículas lípidicas. |
| WO2022221695A1 (en) | 2021-04-17 | 2022-10-20 | Intellia Therapeutics, Inc. | Lipid nanoparticle compositions |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| EP4352247A1 (en) | 2021-06-09 | 2024-04-17 | GlaxoSmithKline Biologicals s.a. | Release assay for determining potency of self-amplifying rna drug product and methods for using |
| US20250127809A1 (en) | 2021-06-23 | 2025-04-24 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| CN115703714B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| KR20240046247A (ko) | 2021-08-19 | 2024-04-08 | 머크 샤프 앤드 돔 엘엘씨 | 열안정성 지질 나노입자 및 그의 사용 방법 |
| CN115710193B (zh) * | 2021-08-23 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| CA3229889A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
| CN115745942B (zh) * | 2021-09-03 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| JP7585166B2 (ja) * | 2021-09-08 | 2024-11-18 | 株式会社東芝 | 物質送達キャリア及び組成物 |
| KR20240123832A (ko) | 2021-12-16 | 2024-08-14 | 아퀴타스 테라퓨틱스 인크. | 지질 나노입자 제형에 사용하기 위한 지질 |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| CN118922178A (zh) | 2022-03-23 | 2024-11-08 | 内诺维什疗法股份有限公司 | 含有高甾醇的脂质纳米颗粒 |
| CN114605791A (zh) * | 2022-03-28 | 2022-06-10 | 济南际通智能制造有限公司 | 一种扎带及其制备方法 |
| AU2023244571A1 (en) | 2022-04-01 | 2024-10-10 | Nanovation Therapeutics Inc. | Mrna delivery method and composition thereof |
| CN115626983A (zh) * | 2022-04-27 | 2023-01-20 | 北京清科胜因生物科技有限公司 | 一种聚(2-噁唑啉)脂质及脂质纳米颗粒 |
| WO2023228116A1 (en) | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
| CN114805460B (zh) * | 2022-05-31 | 2023-10-24 | 温州大学 | 一种dna-胆固醇功能化树状分子杂化体及合成方法与应用 |
| CN119604304A (zh) | 2022-06-18 | 2025-03-11 | 葛兰素史克生物有限公司 | 包含非翻译区或编码来自严重急性呼吸道冠状病毒2奥密克戎毒株刺突蛋白的区段的重组rna分子 |
| CA3266697A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN |
| AU2023347320A1 (en) | 2022-09-23 | 2025-04-10 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| EP4637812A1 (en) | 2022-12-19 | 2025-10-29 | GlaxoSmithKline Biologicals S.A. | Hepatitis b compositions |
| CN120641573A (zh) | 2022-12-22 | 2025-09-12 | 英特利亚治疗股份有限公司 | 用于分析脂质核酸组装体的核酸运载物的方法 |
| EP4658239A1 (en) | 2023-02-03 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024192528A1 (en) * | 2023-03-22 | 2024-09-26 | Nanovation Therapeutics Inc. | Ionizable anionic lipids |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| AU2024269676A1 (en) | 2023-05-08 | 2025-11-06 | Merck Sharp & Dohme Llc | Polynucleotides encoding norovirus vp1 antigens and uses thereof |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024238700A1 (en) | 2023-05-15 | 2024-11-21 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024243031A2 (en) | 2023-05-19 | 2024-11-28 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2024243172A2 (en) * | 2023-05-23 | 2024-11-28 | University Of Florida Research Foundation, Inc. | Solution-processable chiral nanostructures, methods of making, and uses thereof |
| WO2024254226A1 (en) | 2023-06-09 | 2024-12-12 | Merck Sharp & Dohme Llc | Nanoemulsion adjuvant compositions for human papillomavirus vaccines |
| WO2025011529A2 (en) | 2023-07-07 | 2025-01-16 | Shanghai Circode Biomed Co., Ltd. | Circular rna vaccines for seasonal flu and methods of uses |
| WO2025045142A1 (en) | 2023-08-29 | 2025-03-06 | Shanghai Circode Biomed Co., Ltd. | Circular rna encoding vegf polypeptides, formulations, and methods of uses |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025171300A1 (en) * | 2024-02-07 | 2025-08-14 | General Therapeutics, Inc. | Lipids and lipid nanoparticles comprising the same |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025229572A1 (en) | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5345374B2 (OSRAM) * | 1974-12-28 | 1978-12-06 | ||
| US4166132A (en) | 1977-08-18 | 1979-08-28 | Pfizer Inc. | Antiviral amine derivatives of glycerol and propanediols |
| US4173641A (en) * | 1978-05-15 | 1979-11-06 | Pfizer Inc. | Di-O-n-alkyl glycerol derivatives as immune stimulants |
| EP0188311A3 (en) | 1985-01-07 | 1988-07-20 | Syntex (U.S.A.) Inc. | Pharmaceutical formulation of nicardipine and 1,2-dioxy-omega-trialkylammonium compounds |
| AU594654B2 (en) | 1985-01-07 | 1990-03-15 | Syntex (U.S.A.) Inc. | 1,2 dialkoxy-omega-trialkylammonium cationic surfactants |
| CA1267087A (en) * | 1985-02-14 | 1990-03-27 | Nicolaas Visser | Synthetic immunogen |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| ATE217347T1 (de) | 1992-12-04 | 2002-05-15 | Univ Yale | Diagnose mittels signalverstärkung durch ein ribozym |
| WO1994013791A1 (en) | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
| US5871914A (en) | 1993-06-03 | 1999-02-16 | Intelligene Ltd. | Method for detecting a nucleic acid involving the production of a triggering RNA and transcription amplification |
| WO1995008986A1 (en) | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
| US6166197A (en) * | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| WO1997048712A1 (fr) | 1996-06-17 | 1997-12-24 | Nippon Shinyaku Co., Ltd. | Derives asialotrisaccharide moranoline et medicaments |
| US5989912A (en) * | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5849902A (en) * | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| AU724627B2 (en) | 1996-12-19 | 2000-09-28 | Yale University | Bioreactive allosteric polynucleotides |
| JPH10251152A (ja) | 1997-03-14 | 1998-09-22 | Nippon Shinyaku Co Ltd | 虚血再灌流障害治療剤 |
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| JP2002506612A (ja) | 1997-12-05 | 2002-03-05 | デューク・ユニバーシティー | 核酸仲介ｒｎａタグ付けおよびｒｎａ修復 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO1999033791A1 (en) | 1997-12-26 | 1999-07-08 | Nippon Shinyaku Co., Ltd. | Aliphatic derivatives |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| IL126731A0 (en) | 1998-10-23 | 1999-08-17 | Intelligene Ltd | A method of detection |
| WO2000026226A1 (en) | 1998-11-03 | 2000-05-11 | Yale University | Multidomain polynucleotide molecular sensors |
| US6656498B1 (en) | 1998-11-25 | 2003-12-02 | Vanderbilt University | Cationic liposomes for gene transfer |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| JP2000281569A (ja) | 1999-03-25 | 2000-10-10 | Nippon Shinyaku Co Ltd | 脊髄障害治療剤 |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| CN1311189A (zh) * | 2000-03-01 | 2001-09-05 | 沈阳药科大学 | 聚乙二醇单甲醚胆固醇琥珀酸酯衍生物的合成及其制剂 |
| JP2002212477A (ja) * | 2001-01-19 | 2002-07-31 | Fuji Photo Film Co Ltd | インクジェット用インク |
| US20080207542A1 (en) | 2002-03-26 | 2008-08-28 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| EP2489737A1 (en) | 2003-08-28 | 2012-08-22 | Novartis AG | Interfering RNA duplex having blunt-ends and 3'-modifications |
| AU2004272646B2 (en) * | 2003-09-15 | 2011-11-24 | Arbutus Biopharma Corporation | Polyethyleneglycol-modified lipid compounds and uses thereof |
| KR101356935B1 (ko) * | 2004-05-05 | 2014-01-28 | 사일런스 테라퓨틱스 아게 | 지질, 지질 복합체 및 이들의 용도 |
| ATE450251T1 (de) | 2004-05-17 | 2009-12-15 | Tekmira Pharmaceuticals Corp | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung |
| EP1766035B1 (en) | 2004-06-07 | 2011-12-07 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
| EP1773857A4 (en) * | 2004-07-02 | 2009-05-13 | Protiva Biotherapeutics Inc | THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| GB0418172D0 (en) | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
| WO2007086883A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| JP2009509566A (ja) * | 2005-10-03 | 2009-03-12 | サーナ・セラピューティクス・インコーポレイテッド | 低分子干渉核酸を用いた、ｒｎａ干渉によって媒介される、インフルエンザウイルス遺伝子発現の阻害 |
| TW200800235A (en) | 2005-10-18 | 2008-01-01 | Otsuka Pharma Co Ltd | Carrier composition for nucleic acid transport |
| CN101605892A (zh) * | 2005-12-19 | 2009-12-16 | 瑟纳治疗公司 | Rna干扰介导的丙型肝炎病毒的抑制 |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| EP2052079A2 (en) * | 2006-07-17 | 2009-04-29 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| MX2009003548A (es) * | 2006-10-03 | 2009-04-15 | Alnylam Pharmaceuticals Inc | Formulaciones que contienen lipidos. |
| US8466255B2 (en) * | 2007-02-05 | 2013-06-18 | Nippon Shinyaku Co., Ltd. | Polyethylene glycol derivative |
| EP2131848A4 (en) * | 2007-02-16 | 2012-06-27 | Merck Sharp & Dohme | COMPOSITIONS AND METHODS FOR REINFORCED ACTIVITY OF BIOLOGICAL ACTIVE MOLECULES |
| NZ580707A (en) | 2007-05-04 | 2011-11-25 | Marina Biotech Inc | Acylated cationic amino acids and uses thereof |
| CN101903018B (zh) * | 2007-10-17 | 2012-09-05 | 韩国科学技术院 | 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法 |
| CN101468203B (zh) * | 2007-12-25 | 2012-06-27 | 沈阳药科大学 | 可断裂聚乙二醇脂质衍生物的制备方法以及应用 |
| ES2535419T3 (es) * | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Silenciamiento de expresión de quinasa tipo polo usando ARN interferente |
| WO2009086558A1 (en) * | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| WO2009129387A2 (en) | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
| WO2010009065A2 (en) | 2008-07-15 | 2010-01-21 | Novartis Ag | Amphipathic peptide compositions |
| EA037404B1 (ru) | 2008-11-10 | 2021-03-24 | Арбутус Биофарма Корпорэйшн | Липиды и композиции для доставки лекарственных средств |
| WO2010054384A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Lipids and compositions for the delivery of therapeutics |
| US9181295B2 (en) * | 2009-08-20 | 2015-11-10 | Sirna Therapeutics, Inc. | Cationic lipids with various head groups for oligonucleotide delivery |
| SG181904A1 (en) * | 2009-12-23 | 2012-07-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
-
2010
- 2010-12-21 SG SG2012046728A patent/SG181904A1/en unknown
- 2010-12-21 BR BR112012015755-8A patent/BR112012015755B1/pt active IP Right Grant
- 2010-12-21 KR KR1020127019236A patent/KR101762466B1/ko active Active
- 2010-12-21 WO PCT/EP2010/070412 patent/WO2011076807A2/en not_active Ceased
- 2010-12-21 AU AU2010334911A patent/AU2010334911A1/en not_active Abandoned
- 2010-12-21 CN CN201080064582.XA patent/CN102905763B/zh active Active
- 2010-12-21 MX MX2012007450A patent/MX348474B/es active IP Right Grant
- 2010-12-21 CA CA2785492A patent/CA2785492C/en active Active
- 2010-12-21 CA CA3009891A patent/CA3009891C/en active Active
- 2010-12-21 JP JP2012545302A patent/JP2013515693A/ja not_active Withdrawn
- 2010-12-21 US US12/974,906 patent/US20110200582A1/en not_active Abandoned
- 2010-12-21 SG SG10201407996PA patent/SG10201407996PA/en unknown
- 2010-12-21 EP EP20173135.3A patent/EP3721943A1/en active Pending
- 2010-12-21 EA EA201200939A patent/EA026374B1/ru not_active IP Right Cessation
- 2010-12-21 EP EP10796052A patent/EP2516010A2/en not_active Withdrawn
- 2010-12-22 TW TW099145423A patent/TWI549699B/zh active
- 2010-12-27 AR ARP100104953 patent/AR079745A1/es active IP Right Grant
-
2014
- 2014-03-04 US US14/197,124 patent/US9301923B2/en active Active
-
2015
- 2015-10-02 JP JP2015196915A patent/JP6166321B2/ja active Active
-
2017
- 2017-06-22 JP JP2017122319A patent/JP6585659B2/ja active Active
-
2019
- 2019-09-05 JP JP2019162148A patent/JP6940567B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515693A5 (OSRAM) | ||
| US20250312490A1 (en) | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety | |
| US10337014B2 (en) | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | |
| CA2993350C (en) | Multiligand agent for drug delivery | |
| AU2010249881B2 (en) | Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules | |
| US9012225B2 (en) | Lipophilic polynucleotide conjugates | |
| KR101762466B1 (ko) | 지질, 지질 조성물 및 이의 사용 방법 | |
| EP3733647B1 (en) | Cationic lipid | |
| WO2013016058A1 (en) | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery | |
| EP3476832A1 (en) | Cationic lipid | |
| BR112014016562B1 (pt) | Estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação | |
| US10933081B2 (en) | Myostatin iRNA compositions and methods of use thereof | |
| CN114945556B (zh) | 用于核酸转染的类脂质及其用途 | |
| US20250049729A1 (en) | Poegma-based lipid nanoparticles | |
| US20120107389A1 (en) | Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference | |
| CN118105357B (zh) | 一种鞘内递送制剂及其用途 | |
| WO2025256540A1 (en) | Compositions and method for targeted gene delivery | |
| WO2025111578A1 (en) | Linkers coupling functional ligands to macromolecules | |
| CN120081892A (zh) | 一种可电离阳离子脂质化合物及其应用 | |
| CN120271651A (zh) | 一种用于核酸递送的可电离阳离子脂质化合物和组合物及其应用 | |
| CN120227354A (zh) | 一种用于递送核酸的脂质纳米颗粒及其制备方法和用途 | |
| CN120081891A (zh) | 一种可电离阳离子脂质化合物及其应用 | |
| CN121154575A (zh) | 一种氢键辅助的两组分脂质纳米粒及其制备方法与应用 | |
| CN120040464A (zh) | 一种新型可电离脂质分子的制备和应用 | |
| CN120230169A (zh) | 一种可电离阳离子脂质化合物及其应用 |